EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

AstraZeneca (GB:AZN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

Tagrisso is already approved as a first- and second-line treatment for EGFR-positive NSCLC and has become AZ’s best-selling drug, bringing in almost $3.2 billion last year and rising another 56% ...

Tagrisso is already a blockbuster bringing in revenues of more than $3.1 billion in the first nine months of this year, and the new indication will add further momentum to AZ's biggest selling ...

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer.

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

(Alliance News) - AstraZeneca PLC on Thursday said that its cancer drug Tagrisso has been approved in the US for certain type of lung cancer. (Sharecast News) - AstraZeneca announced on Thursday ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...